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Calix[n]arenesAn efficient method for the synthesis of quinolines using microwave irradiation was developed providing
28 quinolines with good yields. The reaction procedures are environmentally friendly, convenient, mild
and of easy work-up. Quinolines were evaluated for their antifungal, anticancer and antioxidant proper-
ties and exhibited high activities in all tests performed.
 2016 Elsevier Ltd. All rights reserved.1. Introduction
The quinolinic core is repeatedly found in various natural and
synthetic products, including several important clinically used
drugs and pharmaceutical candidates.1 Some 2,4-disubstituted
quinolines have been reported as anti-tuberculosis2 and
anthelmintic3 agents and also effective for the treatment of
leishmaniasis, a protozoan disease widespread in tropical areas
of South America.4 Functionalized aminoquinolines5 and
2-heteroarylquinolines6 have been reported as potential antifungal
agents. Synthesized amido and ureido quinoline derivatives substi-
tuted with 2-N-methylamido-pyridin-4-yloxy group effectively
inhibited the proliferation of renal carcinoma, ovarian and lung
cancer cells with potency higher than that of sorafenib, a reference
drug.7 Diarylureas containing a 4-aryl-8-amino(acetamido)quino-
line moiety are notable for their activities against melanoma cells
as they exhibited concentration necessary to inhibit cell prolifera-tion by 50% (IC50) in the order of nanomolar.8 Some quinoline
hybrids with chalcogenide9, ferrocene10 or coumarins11 were
shown to be good antioxidants.
Due to the broad range of applications in medicinal, industrial
and bioorganic processes and in the synthetic organic chemistry
area, there has been an increasing interest in developing efficient
methods for the synthesis of quinolines. A variety of synthetic
methods have been developed for obtaining 2,4-disubstituted
quinolines,12 in which the three-component Povarov reaction13
has been proved to be the most empowering and versatile
approach. Indeed, the three-component Povarov reaction is as
convenient as the classical synthesis for this purpose in terms of
efficacy, speed and atom economy. Then, the Povarov reaction,
based on an inverse electron-demand aza-Diels–Alder reaction
between an aniline, aldehyde and an electron-rich alkene to afford
a tetrahydroquinoline, quinoline or julolidine, has long attracted
the interest of synthetic chemists. This three-component reaction
is reported to be catalyzed by BF3/Et2O,14 lanthanide(III) triflates,15
molecular iodine,16 SnCl2,17 TMSCl,18 TEMPO salt (T+BF4),19
fluorinated alcohols,20 AG50W-X2 resin,21 cellulose sulphuric
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have used calix[n]arenes as organocatalysts in multicomponent
reactions (MRCs),24 including a Povarov reaction designed for the
synthesis of julolidines.25 Recently, we have reported the direct
synthesis of 2,4-disubstituted quinolines using the Povarov reac-
tion among anilines, benzaldehyde and styrene followed by
in situ oxidation assisted by the catalyst p-sulfonic acid calix[4]
arene (CX4SO3H).13a Despite the good yields obtained from a
single step reaction (38–71%), the formation of 2,4-disubstituted
quinolines occurred after long periods of reaction incubation
(12 h) in the presence of acetonitrile as the solvent.
Microwave-assisted organic synthesis has become an interest-
ing tool in organic synthesis for obtaining desired products from
environmentally-friendly reactions based on the use of catalysts
and free of solvents. Atom-economical processes have collectively
contributed to promote the school of modern synthesis.26 To the
best of our knowledge, the use of microwave irradiation to pro-
mote the Povarov reaction is still underexplored.27 Additionally,
the design of an efficient and green approach based on the applica-
tion of a reusable catalyst for the synthesis of 2,4-disubstituted
quinolines is of great interest.
In this work, we investigated a simple and efficient protocol for
the microwave-assisted synthesis of a series of 2,4-disubstituted
quinolines under solvent-free conditions, with potential to inhibit
the growth of fungal of clinical interest and proliferation of cancer
cells and to scavenge free radicals.2. Results and discussion
2.1. Synthesis of quinolines
A series of solvents as well as solvent-free conditions (Table 1)
were tested to determine the best condition for obtaining quino-
lones in good yields. For this purpose, a model reaction constituted
of 4-bromoaniline (1a), benzaldehyde (2a) and styrene (3) was
chosen and carried out in the presence of p-sulfonic acid calix[4]
arene (CX4SO3H) as catalyst (1 mol%) under microwave irradiation.
The use of ethanol or water as protic solvents yielded the quinoline
Q1 in only 8% and 5%, respectively, in which the imine I1 was iso-
lated as the major product (up to 27% yield) and the amine A1 in up
to 15% yield, respectively (Table 1, entries 1 and 2).Table 1
Optimization of the reaction conditions.a
Entry Solvent CX4SO3H (mol%)
1 Ethanolb 1.0
2 Waterb 1.0
3 Acetonitrileb 1.0
4 DCMb 1.0
5 Nonec 1.0
6 Nonec 0.5
7 Nonec 2.0
8 Nonec 5.0
9 Nonec 0.0
a Reagents and conditions: 4-bromoaniline 1a (1.0 mmol), benzaldehyde 2a (1.2 mmol
b Under reflux.
c Reactions at 200 C.
d Isolated yield. DCM, dichloromethane.The Q1 was also obtained in low yield when aprotic solvents,
such as acetonitrile or dichloromethane were used, conditions that
yielded I1 in almost 50% and A1 in 12% in reactions performed with
the former solvent (Table 1, entries 3 and 4). Under solvent-free
conditions, the quinoline Q1 was isolated in 64% yield along with
imine I1 in 20% yield. Once determined that a solvent-free reaction
was the best condition to obtain Q1, we further investigated the
minimum amount of catalyst (CX4SO3H) required to achieve the
maximum reaction yield. The Q1 yield decreased to 43% when
the amount of CX4SO3H was diminished from 1.0 mol% to
0.5 mol% (Table 1, entry 6). No further yield increment was
achieved when the concentration of CX4SO3H was increased from
1 to 2 mol% (Table 1, entry 7). The use of CX4SO3H at 5 mol% pro-
vided Q1 at 58% (Table 1, entry 8). No detectable amount of Q1was
observed in reaction devoid of catalyst, a condition that yielded the
imine I1 at 30% (Table 1, entry 9). Overall, the use of solvent-free
conditions and 1 mol% CX4SO3H as catalyst provided the highest
Q1 yield (64%) from Povarov reaction in which 20% of the substrate
aniline was converted to some byproducts (Table 1, entry 5).
By using the optimal reaction conditions, it was found that the
incubation of reactions at 150, 200 or 250 C for 5 or 10 min
yielded undetectable amounts of Q1 (Table 2, entries 1–6). Similar
results was achieved when reaction were incubated at 150 C for
15 min (Table 2, entry 7). The Q1 yield of up to 35% was verified
from incubation of reactions at 200 to 250 C for 15 min (Table 2,
entries 8 and 9). Longer periods of reaction incubation
(20–25 min) at the maximum temperature of 200 C provided the
best yields for Q1 (Table 2, entries 11 and 14).
Notably, the highest yield was obtained for the model reaction
carried out in an open vessel in the presence of 1 mol% CX4SO3H,
under acetonitrile for 12 h and oil bath (80 C) (Table 2, entry
16).13a
Once determined the best mild conditions to synthesize quino-
lines from the Povarov reaction, we next examined the scope of
this reaction by varying the aldehydes employed as shown in
Fig. 1. The classical thermal method using acetonitrile under 12 h
reflux13a was adopted for obtaining Q1–Q28 for comparison
purpose (Fig. 1).
With respect to the reactions using 4-bromoaniline, similar
yields were observed for obtaining Q1–Q13 using either the
conventional heating or microwave approaches regardless of theQ1 yield (%)d I1 yield (%)d A1 yield (%)d
8 20 15
5 27 11
15 13 12
15 47 –
64 20 –
43 15 –
65 16 –
58 17 –
0.0 30 20
) and styrene 3 (1.5 mmol) for 20 min under power of 50 W in a sealed tube.
Table 2
Effect of temperature and incubation time on the production of quinolines.a
Entry Temperature (C) Time (min) Yield Q1 (%)b Yield I1 (%)b
1 150 5 – 20
2 200 5 – 24
3 250 5 – 29
4 150 10 – 33
5 200 10 – 45
6 250 10 – 44
7 150 15 – 36
8 200 15 30 30
9 250 15 35 20
10 150 20 24 47
11 200 20 64 20
12 250 20 38 34
13 150 25 26 45
14 200 25 65 16
15 250 25 42 26
16c 80 720 65 13
a Reagents and conditions: 4-bromoaniline/benzaldehyde/styrene (molar ratio of 1.0;1.2;1.5) in sealed tube.
b Isolated yield.
c Conventional heating (80 C) in the presence of acetonitrile.
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ing AOH or ANO2 provided the corresponding quinoline in poor
yields (< 20%). Additionally, cyclohexanecarboxaldehyde furnished
the corresponding quinoline (Q7) in yields equal to or lower than
35% (Fig. 1).
The use of microwave irradiation and different aniline sub-
strates led to the formation of quinolines in better yields as
attested by the results obtained for the synthesis of Q14–Q28
(Fig. 1). Indeed, the microwave irradiation was determined to be
in the range from 11% to 19% more efficient than conventional
heating for obtaining the quinolines Q16, Q18, Q21 and Q25 while
the yield of Q26 using the former approach was twice as higher as
that of the latter ones (Fig. 1). Reactions under microwave irradia-
tion furnished the desired quinolines more rapidly when compared
with those under thermal heating and solvent-free conditions.
The mechanism that drives Povarov reaction is still under
debate, in which the most widely accepted one involves a stepwise
sequence via ionic intermediates generated by a Mannich-like
reaction, followed by an intramolecular electrophilic aromatic sub-
stitution.28 Based on this, a mechanism for the formation of the
functionalized quinolines herein described is hypothesized in
Scheme 1. The first step consists of the reaction between aniline
and the activated aldehyde to provide the iminium via Mannich
reaction. The reaction with iminium, after styrene addition, forms
the corresponding carbocation. Then, an intramolecular elec-
trophilic aromatic substitution takes place to furnish the tetrahy-
droquinoline, which is further oxidized to the corresponding
quinoline.
The ion exchange capacity of the catalyst was determined by
acid-base titration29 using 5 mM NaOH (aq). A total of 8.6 mmol
of H+ g1 were necessary to completely titrate CX4SO3H. This result
is consistent as the catalyst bears eight strong acid sites (four
ASO3H and four AOH groups).
The potential of CX4SO3H to be reused in the reaction to obtain
quinolines was also investigated. The CX4SO3H could be success-
fully used up to five successive reactions without significant loss
of catalytic power (Fig. 2). The catalyst was easily recovered fromthe reaction by liquid-liquid extraction with water and dichloro-
methane followed by evaporation of aqueous phase under reduced
pressure. As a result, the reaction model constituted of 4-bro-
moaniline (1a), benzaldehyde (2) and styrene (3) could still afford
quinoline Q1 in good yield even after five cycles (Fig. 2).2.2. Antifungal activities
Because of the need to develop new structures with antifungal
activity30 and considering that other quinoline-bearing structures
have shown promising antifungal activities,31 the 2,4-disubstituted
quinolines synthesized were tested against some fungi of clinical
interest such as Candida albicans and Cryptococcus neoformans.
The C. albicans is the etiological agent of many opportunistic infec-
tions in immunocompromised hosts32 while C. neoformans causes
cryptococcal meningitis, one of the most important HIV-related
fatal opportunistic mycosis that has killed to date over 650,000
immunocompromised patients worldwide.30c Although the
incidence of HIV tends to decrease in countries with highly
active anti-retroviral therapy, fungal infections remain a serious
problem for AIDS patients. As a consequence, the design of
compounds with anti-cryptococcal activity is very desirable.33
To better understand the results of MIC values for inhibition of
fungal growth, the quinolines synthesized were divided into three
categories: (i) group I, comprised the non-substituted or 2-posi-
tion-substituted benzene ring quinolines; (ii) group II represented
by Q7 that bears a 2-cyclohexyl ring and (iii) represented by Q13
that bears a 2-furyl substituent at 2-position of the quinoline ring
(Table 3). Group I was further subdivided in I.1, in which were
grouped quinolines (Q1–Q6 and Q8–Q12) that possess a ABr sub-
stituent at 6-position (R2) of quinoline skeleton and a variety of
substitution at 2-position (R4, R5 and/or R6) of the benzene ring.
The subgroup I.2, on the other hand, includes compounds (Q14–
Q28) that present a phenyl group at 2-position of the quinoline
ring with a variety of substituents at positions 5 (R1), 6 (R2) and
7 (R3) of this same core.
Fig. 1. Synthesis of 2,4-disubstituted quinolines employing CX4SO3H as catalyst.
Yields in green were obtained by microware (MW) and yields in blue were obtained
by conventional heating (CH). MW: 200 C, 20 min, solvent-free. CH: 80 C,
acetonitrile, 12 h. Q14–Q28 synthesis by Simões et al., 2014.13a
Scheme 1. Mechanistic proposal for the synthesis of quinolines from Povarov
reaction.
Fig. 2. Recovery and potential of CX4SO3H to be reused as catalyst in Povarov
reaction for the synthesis of 2,4-disubstituted quinolines. MW, microwave heating
and CH, conventional heating.
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from experiments of fungal growth inhibition in the presence of
quinolines or amphotericin B (Amph B; reference drug) in the
range from 3.9 to 250 lg mL1 (Table S1; Supplementary material).
The MIC80 and MIC50 values correspond to the minimumconcentration of a compound-test necessary to inhibit the fungus
growth by 80% and 50%, respectively. Such values are well accepted
in the literature as representative of the in vitro activity of target
compounds.34
Quinolines Q1–Q3, Q6–Q8, Q13–Q28 inhibited C. albicans
or/and C. neoformans growth at different extents (Table 3). The
C. neoformans, however, was shown to be more sensitive to the
quinolines tested (MIC50 values lower than 250 lg mL1) than
did C. albicans.
To determine the influence of the substituent at 2-position of
the quinoline ring, we evaluated the percentage of growth inhibi-
tion towards C. albicans or C. neoformans as a function of the con-
centration of Q1, Q7 and Q13. The quinoline bearing a furan ring
at 2-position (Q13) effectively inhibited the growth of both fungi
tested acting in a concentration-dependent mode on C. neoformans
and exhibiting maximum inhibitory effect (78%) on C. albicans
when used at 125 lg mL1 (Fig. 3). A maximum growth inhibition
of around 55% was achieved from C. albicans incubation with
62.5 lg mL1 Q1 (bearing a 2-phenyl group) while a much higher
concentration (4-fold) of this same quinoline was required to have
similar effect on C. neoformans. The Q7, which bears a cyclohexyl at
2-position, was the least effective against C. albicans and
C. neoformans (Fig. 3). Overall, the presence of a heteroaromatic
ring at 2-position of quinolic ring boosts the antifungal activity
of quinolines.
When considering all the other quinolines synthesized, almost
all compounds belonging to the subgroup I.1 were determined to
be poor antifungals against C. albicans. On the other hand, some
of them exhibited relatively low MIC50 values activity against C.
neoformans. Indeed, the most active compounds (MIC50 values
lower than 16 lg mL1) possess AF (Q3) or ACH3 (Q5) as R5 group
(Table 3). Compound Q6, which presents a Ap-OCH3 as R5 group
and two other AOCH3 groups as R4 and R6, exhibited moderate
activity (MIC50 lower than 65.0 lg mL1). Notably, the presence
of ACl, AOCH3, ANO2, and ACN as R5 group and ANO2 as R6 group
negatively affected the activity of quinolines as attested by the
results of MIC values obtained for Q2, Q4, Q10, Q11 and Q12
(Table 3). On the other hand, compounds belonging to subgroup
I.2 that bear ANO2 or ACF3 groups, either at 6- (R2; Q17) or 7-posi-
tion (R3; Q24) presented similar effects on C. neoformans (Table 3).
Quinolines presenting ACl, ASCH3, AC(CH3)3, AOCH2O or AOCH3
at 6-position (Q19, Q20, Q23, Q26, Q27 and Q28) were very active
against C. neoformans. Compound Q26 was also identified as the
only effective against C. albicans (Table 3). The presence of AOH
at 7-position (Q14) enhances 8-fold the antifungal activity against
C. neoformans when compared with a non-substituted quinoline at
similar position (Q15).
Table 3
Effect of quinolines on the growth of Candida albicans ATCC 10231 and Cryptococcus neoformans ATCC 32264.
N
R1
R2
R3
R4
R5
R6
N
Br
N
Br
O
(I) (II) (III)
Compounds Category R1 R2 R3 R4 R5 R6 C. albicans C. neoformans
MIC80 MIC50 MIC80 MIC50
Q1 I.1 H Br H H H H >250.0 125.0 >250.0 31.2
Q2 H Br H H Cl H >250.0 250.0 >250.0 250.0
Q3 H Br H H F H >250.0 >250.0 >250.0 15.6
Q4 H Br H H OMe H >250.0 >250.0 >250.0 >250.0
Q5 H Br H H Me H >250.0 >250.0 >250.0 15.6
Q6 H Br H OCH3 OCH3 OCH3 250.0 125.0 250.0 62.5
Q8 H Br H H OH H 125.0 62.5 250.0 62.5
Q9 H Br H H H OH >250.0 >250.0 >250.0 >250.0
Q10 H Br H H NO2 H >250.0 >250.0 >250.0 >250.0
Q11 H Br H H H NO2 >250.0 >250.0 >250.0 >250.0
Q12 H Br H H CN H >250.0 >250.0 >250.0 >250.0
Q14 I.2 H H OH H H H >250.0 >250.0 >250.0 15.6
Q15 H OH H H H H >250.0 250.0 250.0 125.0
Q16 H F H H H H >250.0 250.0 >250.0 >250.0
Q17 H NO2 H H H H >250.0 >250.0 250.0 125.0
Q18 H CF3 H H H H >250.0 >250.0 250.0 250.0
Q19 H Cl H H H H >250.0 >250.0 >250.0 15.6
Q20 H SCH3 H H H H >250.0 250.0 31.2 15.6
Q21 H CN H H H H >250.0 250.0 250.0 125.0
Q22 H CO2H H H H H >250.0 250.0 >250.0 250.0
Q23 H C(CH3)3 H H H H >250.0 >250.0 15.6 3.9
Q24 H H NO2 H H H >250.0 250.0 >250.0 125.0
Q25 H Cl CF3 H H H >250.0 250.0 >250.0 250.0
Q26 OCH3 OCH3 OCH3 H H H 125.0 125.0 15.6 7.8
Q27 H OCH2O H H H >250.0 >250.0 250.0 31.2
Q28 H OCH3 H H H H >250.0 250.0 250.0 31.2
Q7 II – – – – – – >250.0 250.0 >250.0 250.0
Q13 III – – – – – – 125.0 62.5 250.0 62.5
Amph B 0.12 0.06 0.25 0.12
MIC80 and MIC50 values correspond to the concentration of compound tested necessary to inhibit fungus growth by 80% and 50%, respectively. Values were calculated using
the logistic concentration-response curve obtained by four-parameter SigmaPlot version 11 (Systat Software, Inc., San Jose, California, USA). Amph B, amphotericin B
(reference drug).
Fig. 3. Comparative antifungal activities of Q1, Q7 and Q13 against C. albicans ATCC 10231 (a) and C. neoformans ATCC 32264 (b).
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2,4-disubstituted quinolines and their derivatives. The Q13 was
the most active among the 2-substituted compounds (bearing
A2-phenyl, 2-cyclohexyl or 2-furan) containing ABr at 6-position.
Then, this opens an opportunity for the synthesis of a new series
of potential antifungal quinolines bearing a furan ring. Within
6-brominated compounds (I.1 category), the most active were
those solely substituted at the 2-phenyl group (Q3 with R5 = F
and Q5 with R5 = CH3). Likewise, the 30,40,50-OCH3 derivative (Q6)
wasmore active than the correspondingmonosubstituted one (Q4).2.3. Antiproliferative assays
Cell proliferation was determined using the MTT assay with
absorbance measurements at 540 nm. All synthesized quinolines
(Q1–Q28) were evaluated in vitro against the following cancer cell
lines: NCI-H226 (lung), TOV-21G (ovary) and Hep-2c (Hela con-
taminant). Compounds were also tested against a non-cancerous
human cell line (CCD 19-Lu; lung fibroblast) to determine the
selective index (SI). Data (Fig. 4) were submitted to Analysis of
variance (ANOVA) one factor post-hoc analysis using the Least
Fig. 4. Tumor and non-tumor cell survival after treatment with quinolines. The
y = 0 indicates the 50% survival limit, in which compounds furnishing values higher
than zero show cytostatic effect while those providing values lower than zero are
considered cytotoxic. Differences between groups were analyzed using a non-
parametric test (Kruskal Wallis; P < 0.05).
Fig. 5. Concentration of quinolines required to inhibit the proliferation of some
tumor (Tov21G, Hep2 and NCI-H226) and non-tumor (CCD19-Lu) cells by 50%
(IC50). Asterisks indicate significant difference by ANOVA post hoc LSD test
(P < 0.05).
1158 N.A. Liberto et al. / Bioorganic & Medicinal Chemistry 25 (2017) 1153–1162Significant Difference (LSD) method, which showed statistically
difference only between the control and concentrations of 1000
and 1500 lg mL1.
The concentrations of quinolines that caused cell growth inhibi-
tion by 50% (IC50 values) and the selectivity indexes are summa-
rized in Table 4. The selectivity index compares the cytotoxicity
of a compound against tumor cells and non-tumor cells. The calcu-
lation provides the ratio of IC50 value obtained for the non-tumor
cell line to the IC50 value obtained for the tumor cell line. Regarding
the analysis of selectivity ratios, there is no consensus in the liter-
ature on the threshold values for tumor cell lines. However, it was
found that values greater than 5 are good indicators of
selectivity.35
The IC50 values indicated that Tov21G cells were more resistant
and that NCI-H226 cells were more susceptible to all compounds
tested (Fig. 5). According to the TP53 database of the International
Agency of cancer (http://p53.iarc.fr/CellLines.aspx), the NCI-H226Table 4
Concentration of quinolines required to inhibit the proliferation of tumor cells by 50% (IC
IC50 (lM)
Quinolines TOV-21G CCD19-Lu NCI-H226
Q1 530.7 668.7 43.4
Q2 ND 528.1 1.58
Q3 570.4 ND ND
Q5 ND ND ND
Q6 492.6 104.5 61
Q7 ND 489.5 91
Q8 ND 104.2 8
Q11 ND ND 8.5
Q12 ND ND ND
Q13 876.8 631.1 30
Q14 ND ND ND
Q24 ND ND 558.9
Q27 ND 354.1 40
Q28 110.5 924.9 57
Nd: not determined. The IC50 value was calculated using the non-linear regression obtacell line is TP53 mutated while the TOV21G is wild-type. This
mutation could explain the differences of cell survival observed
for the tumor lines studied when incubated with quinolines, as
TP53 gene encodes for a tumor suppressor protein that is responsi-
ble for regulating the expression of target genes related to DNA
repair.
An examination of the association between survival and IC50
values highlighted the compounds that had the most promising
antitumour activities (Fig. 6). The normal cell line CCD19-Lu
proved to be most susceptible to cytotoxicity with quinolines Q7,
Q8, Q27 and Q28, while all were cytotoxic for NCI-H226 cells
(susceptible), and none were cytotoxic for TOV21G (resistant).
The NCI-H226 line was selectively susceptible for the majority of
quinolines and presented the best selective indices. The
NCI-H226 line is an epithelial lung cancer derived from a meta-
static site. It is one of the more aggressive cancer types with a high
incidence and prevalence. These compounds proved at priori to be
one good source of antitumoural molecules for lung cancer. The
TOV21G cells (resistant) were selectively susceptible only to the
Q1, Q3 and Q28 quinolines. The Tov 21G cell line is from an epithe-
lial ovary cancer that is classified as aggressive. Thus, these
compounds proved to be good agents for improving effectiveness50) and respective selective index (SI).
SI (lM)
Hep-2C TOV-21G NCI-H226 Hep-2C
128.1 1 15 5
269.0 ND 356 1
5.0 ND ND ND
175.0 ND ND ND
ND 0 1 ND
ND ND 5 ND
104.8 ND 13 0
ND ND ND ND
98.8 ND ND ND
101.8 0 21 6
ND ND ND ND
ND ND ND ND
951.1 ND 8 0
495.5 8 16 1
ined by OriginPro 7.0.
Fig. 6. Association between IC50 values and viability of human tumor cells (Tov21G,
Hep2 and NCI-H226) and non-tumor cells (CCD19-Lu). The dotted lines show the
50% survival limit, in which values are under these lines are indicative of compound
cytotoxicity. Compounds whose data are under the dotted line are considered the
most promising antitumor agents.
Fig. 7. Values of IC50 for quinolines. The differences among treatments were
analyzed by a non-parametric test (Kruskal Wallis; P < 0.05).
Fig. 8. Potential of quinolines as scavengers of reactive nitrogen species. The
reaction medium consisted of the compound tested (160 lM) and DPPH radicals
(100 lM). Resveratrol (Resv) was used as a positive control. Standard deviations
(SD) were lower than 28.0%. Data are from three independent experiments, each
performed in triplicate.
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against NCI-H226, suggesting that there are different biological
pathways between them. The Hep2c line was susceptible to the
majority of compounds as was NCI-H226, but not in a selective
manner. The results for these cells were meaningless once it was
shown to be a HeLa-contaminated cell line.
The quinoline with lower IC50 values was the one containing a
4-methoxyphenyl group, which indicates that methoxyl group at
4-position improved the antiproliferative activity against lung can-
cer. The most effective substituents on tumor cells (except for
Hep2c cancer cell line) were 4-fluorophenyl, 4-nitrophenyl, 3-
nitrophenyl and cyclohexane (Fig. 7). The presence of activating
groups on the aromatic ring provided promising anticancer
activity.
2.4. Scavenging of reactive nitrogen species (RNS)
The ability of the synthesized quinolines to scavenge reactive
species with unpaired electrons on nitrogen atoms (RNS) was
investigated using the 2,2-diphenyl-1-picrylhydrazyl (DPPH)
method.36 An initial screening was performed to select potential
RNS scavengers. Compounds were tested at 160 lM against
100 lM DPPH using the plant natural product resveratrol (Resv)
as a positive control. Under our experimental conditions, quinoli-
nes Q14, Q15, Q21 and Q26 were determined to be the best DPPH
scavengers because they were able to scavenge 70–85% of the free
radicals. These results are comparable to those obtained for Resv, a
known free radical scavenger (Fig. 8). Quinolines Q1, Q2, Q5, Q7,
Q13, Q17, Q18 and Q28 were also found to be promising DPPH-
capturing compounds; they scavenged free radicals by 45–55%
(Fig. 8). The other quinolines, except for Q11 that was almost inac-
tive, sequestered DPPH by approximately 35–40% (Fig. 8). Overall,
no significant changes were observed in the DPPH scavenging abil-
ity for compounds with structural alterations in both the quinoline
core and the two phenyl rings. However, some structure-activity
relationships can be addressed. For instance, the presence of ahydroxyl group at C6 (compound Q15) or C7 (compound Q14) on
the quinoline moiety was determined to be essential for scaveng-
ing of DPPH. In contrast, a hydroxyl group on the phenyl ring
bound to the C2 of the quinoline core is not mandatory for RNS
scavenging, as Q1 (which is devoid of the corresponding AOH) is
as effective as compounds Q8 and Q9. It is noteworthy that the
presence of an m-NO2 group on the phenyl ring bound to the C2
of the quinoline core compromises the ability of quinoline Q11 to
scavenge DPP radicals. Contrary to Q11, Q10, which bears a p-
NO2 group instead, is able to scavenge DPPH radicals by approxi-
mately 40% (Fig. 8).
The concentration of the compound tested necessary to scav-
enge a free radical by 50% was determined varying the concentra-
tion of quinolines (SC50; Table 5). Compounds Q21 and Q26 were
the most efficient DPPH scavengers, as they exhibited SC50 values
lower than 20 lM. The Q13 was also able to scavenge 50% of the
Table 5
Concentrations of promising quinolines that are necessary to scavenge DPPH or O2
radicals by 50% (SC50 in lM).
Compounds SC50 (lM)
DPPH O2
Q1 >250.0 >250.0
Q2 180.3 >250.0
Q5 197.1 104.3
Q6 428.1 >250.0
Q7 118.5 >250.0
Q9 >250.0 121.4
Q13 82.7 >250.0
Q15 >250.0 >250.0
Q17 104.5 >250.0
Q18 260.6 >250.0
Q21 19.5 220.2
Q23 >250.0 >250.0
Q26 18.9 >250.0
Q28 168.5 >250.0
Resveratrol (Resv) 8.2 255.0
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(Table 5). The order of increasing potency for the other quinolines
is Q17 > Q7 > Q28 > Q2 > Q5 > Q18 > Q6.
2.5. Scavenging of reactive oxygen species (ROS)
A screening was also performed with the synthesized quinoli-
nes to evaluate the ability of such compounds to capture the reac-
tive oxygen species (ROS) superoxide anion (O2). Again, quinolines
were used at 160 lM in a reaction medium in which O2 was arti-
ficially generated. Quinolines Q5, Q8, Q9, Q15, Q17, Q20, Q21, Q23,
Q26 and Q27 were much more efficient in the scavenging of ROS
than Resv, the positive control (Fig. 9). The efficiency of quinolines
Q3, Q4, Q7, Q10, Q12 and Q22 was comparable to that of Resv
(Fig. 9). In contrast to the observations with DPPH scavenging, con-
siderable variations in the efficiency of compounds were observed
toward O2. The presence of a p-toluyl substituent at C2 boosted the
activity of compound Q5 compared to the corresponding quinoline
that bears a phenyl substituent at this same position (compound
Q1). The positive effect observed for Q5 (Fig. 9) is likely due to
the presence of benzylic hydrogens, which may favor the forma-
tion of benzyl radicals, known to be very stable. Electron-Fig. 9. Effect of quinolines on reactive oxygen species. The reaction medium
included artificially-generated superoxide anion (O2) and compounds tested at
160 lM. Resveratrol (Resv) was used as a positive control. Standard deviations (SD)
were lower than 17.0%. Data are from three independent experiments, each done in
triplicate.withdrawing groups (ANO2 and ACN; Q17 and Q21, respectively)
at C6 on the quinoline moiety, except for a 3-fluoromethyl group
(ACF3; Q18), increased the activity of quinolines towards O2
(Fig. 9). In contrast, the presence of electron-withdrawing groups
at C7 (ACO2H and ANO2; Q22 and Q24, respectively) and/or C6
(6-Cl and 7-CF3 Q25) negatively affected the potential of quinolines
to scavenge O2 species (Fig. 9). The presence of a hydroxyl group
(AOH) at C6 (compounds Q14 and Q15) contributes to the O2 scav-
enging activity of quinolines. However, a m-OH group on the phe-
nyl ring bound to the C2 of the quinoline core renders the
compound twice as active as the one bearing a p-OH at the same
position (Q9 and Q8, Fig. 9). The quinoline containing a thiomethyl
group (ASCH3) at C7 (Q20) was 2-fold more active than the corre-
sponding derivative bearing an AOCH3 group (Q28) (Fig. 9). The
presence of more than one AOCH3 group (compound Q26) or a
methylenedioxy (compound Q27), however, boosted the activity
of such quinolines toward O2. Notably, quinoline Q23, which bears
a tert-butyl substituent at C6, was able to scavenge 50% of the O2
artificially generated in the medium. All quinolines bearing halo-
gen atoms (Br, F and Cl; Q1, Q16 and Q19, respectively) and unsub-
stituted phenolic rings demonstrated a lower potential for
scavenging ROS (<10% scavenging) (Fig. 9).
The remaining quinolines were found to be poor O2 scavengers
(Fig. 9). The most promising quinolines were used further to assess
the concentration of compounds necessary to scavenge ROS by 50%
(SC50). Indeed, quinolines Q5 and Q9 were twice as potent as Resv
towards O2 (Table 5).3. Conclusions
A new and efficient method using microwave irradiation and
p-sulfonic acid calix[4]arene as catalyst was developed for the
synthesis of 28 2,4-disubstituted quinolines. Some advantages of
the approach described herein include the use of solvent- and
metal-catalyst-free conditions, short reaction times, recycling cat-
alyst besides the catalyst tolerance towards a wide range of func-
tional groups. Quinolines excelled, as they have good to excellent
free radical scavenging activity being notable as good antifungal
and antiproliferative candidates. The 6-Br-2,4-disubstituted quino-
lines, in particular, are attractive for use as templates for the devel-
opment of new antifungal and antitumor agents.4. Experimental section
4.1. General methods and materials
All starting materials were obtained from commercially avail-
able sources with high-grade purity and were used without further
purification. The p-sulfonic acid calix[4]arene (CX4SO3H) was pre-
pared according to known procedures.37 Reactions did not require
anhydrous conditions. The melting points (uncorrected) of synthe-
sized quinolines were determined using a MQAPF-301 Microquí-
mica micromelting device. Infrared spectra were obtained on a
FT-IR Varian 660 Fourier Transform Infrared spectrometer. The
1H and 13C NMR spectra were obtained on a Varian Mercury spec-
trometry at 300 MHz for 1H and 75 MHz for 13C, in CDCl3. Coupling
constants (J) are reported in Hertz (Hz). High resolution mass spec-
tra (HRMS) were obtained on a Shimadzu LC-IT-TOF Prominence
system.
4.2. General procedure for the synthesis of 2,4-disubstuted quinolines
Microwave (MW) approach: A mixture of an aniline (1 mmol),
aldehyde (1.2 mmol), styrene (1.5 mmol) and p-sulfonic acid calix
[4]arene (1 mol%) was stirred at 200 C for 20 min.
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aldehyde (1.2 mmol), styrene (1.5 mmol), p-sulfonic acid calix[4]
arene and acetonitrile (1 mol%) was stirred at 80 C for 12 h.
Treatments (MW and CH): The reaction was quenched by
addition of water (10 mL) and the product was extracted with
dichloromethane (3  10 mL). The solvent was removed under
reduced pressure in a rotary evaporator. The obtained solid was
obtained was purified by silica gel column chromatography
(hexane/dichloromethane/acetone, 8:2.8:0.1) to afford the quinoli-
nes Q1–Q28 in high purity (Fig. 1). All quinolines were character-
ized by 1H and 13C NMR, IR, HRMS (ESI) and melting points.
4.3. Antifungal activity
4.3.1. Microorganisms and media
For the evaluation of antifungal activity, standardized strains of
C. albicans ATCC 10231 and C. neoformans ATCC 32264 from the
American Type Culture Collection (ATCC, Rockville, MD, USA) were
used. Strains were grown on Sabouraud-chloramphenicol agar
slants for 48 h at 30 C and then maintained on slopes of
Sabouraud-dextrose agar (SDA, Oxoid). Strains were sub-cultured
every 15 days to prevent pleomorphic transformations. Inocula
were obtained according to reported procedures38 and adjusted
to 1–5  103 colony forming units (CFU)/mL.
4.4. Fungal growth inhibition
Yeasts broth microdilutions (technique M27-A3 of CLSI) were
performed in 96-well microtiter plates. For the assay, compound-
test wells (CTWs) were prepared with stock solutions of each com-
pound in DMSO (concentration 6 1%) and diluted with RPMI-1640
to final concentrations in the range from 3.9 to 250.0 lg mL1. An
inoculum suspension (100 lL) was added to each well (final vol-
ume in the well = 200 lL). A growth control well (GCW) (contain-
ing medium, inoculum and the same amount of DMSO used in a
CTW) and a sterility control well (SCW) (sample, medium and ster-
ile water) were included for each fungus tested. Microtiter trays
were incubated in a moist, dark chamber at 30 C for 48 h for both
yeasts. Microtiter plates were read in a VERSA Max microplate
reader (Molecular Devices, Sunnyvale, CA, USA). Amphotericin B
was used as a positive control. Tests were performed in triplicate.
Reduction of growth for each compound concentration was calcu-
lated as it follows: % inhibition = 100  (OD 405 CTW  OD 405
SCW)/(OD 405 GCW  OD 405 SCW). The means ± standard devia-
tions (SD) were used for plotting dose-response curves represent-
ing % inhibition versus concentration of each compound using
SigmaPlot 11.0 software.
4.4.1. MIC80 and MIC50 determinations
Two endpoints were defined from the experiments described
above. Minimum Inhibitory Concentrations 80 (MIC80) and 50
(MIC50) were defined as the minimum concentration that inhibits
80% or 50% of the fungal growth, respectively.
4.5. Antiproliferative assay
Human tumor cell lines CCD-19Lu (ATCC CCL-210TM), WI-26
VA4 (ATCC CCL-95.1TM), HEp-2C (ATCC CCL-23TM) and NCI-H226
(ATCC CLR-5826TM) were cultured in MEN-NEA, EMEM and RPMI
media, respectively (Sigma-Aldrich Co. LLC.) supplemented with
10% foetal bovine serum and 1% L-glutamine in a 37 C humid
atmosphere enriched with 5% CO2. Cells were culture on 96 well
plates (1  105 cells/well) in the presence or absence of synthe-
sized quinolines at concentration in the range from 1.0 to
1000 lg mL1. After 24 h, the samples were sensitized in a MTT
assay, and their absorbances (at 540 nm) measured 3 h later usinga Molecular Devices Spectramax M5E. Values, corresponding the
cell viability, were used to calculate the IC50 values for statistical
analysis purposes.
4.6. Scavenging of reactive nitrogen species
The ability of quinolines Q1–Q28 to scavenge a 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radical, a reactive nitrogen species (RNS),
was determined according to Gülcin,39 with modifications. The
screening of potential candidates was performed by incubating
each compound-test (200 lg mL1) in an ethanolic medium con-
taining 100 lMDPPH. The systems were maintained under stirring
and absence of light for 30 min and the absorbance was measured
at 517 nm. Those compounds with potential scavenging activities
were then tested in the range from 0 to 160 lg mL1 to determine
the concentration necessary to scavenge DPPH radicals by 50%
(IC50). The results presented are from three independent experi-
ments, each performed in triplicate.
4.7. Scavenging of reactive oxygen species
The capacity of quinolines to scavenge superoxide anions (O2)
was evaluated in 50 mM phosphate buffer (pH 7.8) containing
13 mM L-methionine, 75 lM nitroblue tetrazolium, 100 lM EDTA,
2 lM riboflavin and compound-test at 0–200 lg mL1. Reaction
mixtures were incubated for 10 min at 25 C in the presence of flu-
orescent light to induce O2 formation. Controls consisted of reac-
tion mixtures maintained at 25 C for 10 min in the absence of
light. The percentage of O2 scavenged by each compound-test
was determined at 575 nm. The results presented are from three
independent experiments, each performed in triplicate.
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